Skip to main content
spacbrain

Celularity

Closed (deSPAC)

Health Care · cellular therapeutics and placenta-derived cell therapy

What it is
Celularity Inc
What it’s doing now
Merging with GX Acquisition Corp. (GXGX) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR-T cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. To learn more, visit celularity.com.

Source: S-4/A, accession 0001213900-21-031067

What the company says about itself

Web research — not audited

Celularity is a cellular medicine company focused on delivering off-the-shelf allogeneic cellular therapies derived from the placenta. The company operates a 150,000 sq. ft. purpose-built manufacturing, translational research, and biobanking facility, and also offers CDMO services.

Markets:
Cellular Medicine | Biotechnology
Products:
Allogeneic placental-derived cellular therapies | Advanced biomaterials | Cenplacel-L | CDMO services
Customers:
Fountain Life
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$372 million of total … equity value of $1.25 billion." [https://www.prnewswire.com/news-releases/celularity-and-gx-acquisition-corp-announce-merger-agreement-to-create-a-publicly-listed-leader-in-allogeneic-cellular-therapy-301203341.html]

Source: https://celularity.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Celularity is merging with GX Acquisition Corp. (GXGX) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $83M · unsourced

Structure per SEC accession(s) 0001213900-21-004069. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Celularity going public?

Celularity has an approved merger with the SPAC GX Acquisition Corp. (GXGX). Deal status: Closed (deSPAC).

Does Celularity have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals
Same sponsor’s other SPACs
  • GXII — GX Acquisition Corp. II · Closed (deSPAC)